OriGene Technologies, a global leader in gene-centric research tools, today announced an exclusive distributorship and a co-marketing partnership with Nanoportal Biotech for ProteanFect™, an industry-first, coacervate-based gene delivery reagent that promises to redefine transfection in challenging cell types.
ROCKVILLE, Md., Nov. 11, 2025 /PRNewswire-PRWeb/ -- ProteanFect represents a major leap forward in nucleic acid delivery. Unlike conventional lipid- or polymer-based reagents, ProteanFect harnesses mammalian endogenous proteins to deliver plasmid DNA (pDNA) and RNA into notoriously hard-to-transfect cells—including stem cells, neuronal cells, and immune cells. By mimicking nature's own biological mechanisms, ProteanFect achieves unparalleled efficiency, safety, and compatibility, enabling discoveries that were once out of reach.
"This partnership marks an exciting milestone for OriGene and the scientific community," said Dr. Xuan Liu, SVP of OriGene Technologies. "With ProteanFect, we are tackling one of the toughest barriers in gene delivery—making previously difficult experiments achievable. Researchers will now have a powerful new tool to unlock discoveries in regenerative medicine, immunology, neuroscience, and beyond."
Nanoportal Biotech echoed this enthusiasm. "ProteanFect is not just a reagent—it's a solution to a decades-old bottleneck," said Dr. Xiaofei Gao, Founder and President of Nanoportal Biotech. "By teaming up with OriGene, with its trusted brand and global reach, we can empower scientists everywhere to push the boundaries of gene and cell research."
About OriGene Technologies
OriGene Technologies, Inc., headquartered in Rockville, MD, is a global research tools company dedicated to advancing biomedical research and drug discovery. With a portfolio of over 1.3 million products—including cDNA clones, recombinant proteins, antibodies, and assays—OriGene provides scientists worldwide with the tools they need to accelerate genomics and proteomics breakthroughs.
About Nanoportal Biotech
Nanoportal Biotech is pioneering next-generation gene delivery platforms based on natural biological pathways. Its flagship innovation, ProteanFect™, is the world's first coacervate-based nucleic acid delivery system, designed to deliver genetic material with unmatched efficiency and safety across a wide range of cell types. Nanoportal is committed to equipping researchers and collaborators with transformative technologies that power the next era of gene and cell therapy research.
Media Contact
Xuan Liu, OriGene, 1 2406205785, [email protected], OriGene
SOURCE OriGene
Share this article